AURA: AZD9291 Active and Safe in Untreated EGFR Mutation–Positive Advanced NSCLC

May 29-June 2, 2015; Chicago, Illinois
AZD9291, a third-generation irreversible EGFR tyrosine kinase inhibitor, demonstrated an ORR of 73% with few grade ≥ 3 adverse events in previously untreated patients with EGFR mutation–positive, advanced NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 541 KB
Released: June 1, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

On-demand webcast from a live CCO webinar capturing global perspectives from Drs. Edward S. Kim and Luis Paz-Ares on the optimal management of patients with EGFR+ NSCLC

Edward S. Kim, MD, FACP, FASCO Luis Paz-Ares, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: July 29, 2021 Expired: July 28, 2022

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

On-demand webcast from CCO where clinical experts discuss how to optimally integrate the latest clinical data on predictive biomarkers to guide treatment decisions in advanced NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO
Program Director
Stephen V. Liu, MD Lecia V. Sequist, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 26, 2021 Expired: July 25, 2022

In this on-demand webcast from CCO, Mary Jo Fidler, MD, and Scott Gettinger, MD, review the latest advances in immunotherapy for NSCLC through discussion of a series of patient cases.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue